2020 Guide to Patient Support Services

Lilly Oncology (Eli Lilly)

Eli Lilly and Company, through Lilly Oncology, offers financial assistance to qualified patients who are prescribed oncology medications and who need help in paying for their cancer medications.

The Lilly PatientOne Access Services program provides support to patients who are prescribed many Lilly Oncology drugs, including Alimta (pemetrexed), Cyramza (ramucirumab), Erbitux (cetuximab), and Portrazza (necitumumab).

The Verzenio Continuous Care program provides personalized care and financial support to eligible patients who are prescribed the Lilly Oncology medication Verzenio (abemaciclib).

The complete list of Lilly Oncology drugs and their respective programs is provided in the Table.


The Lilly PatientOne Access Services program includes Reimbursement Assistance, the Patient Assistance Program through the Lilly PatientOne Co-Pay Program, and the Lilly Cares Foundation.

For eligible, insured patients, the Lilly PatientOne Co-Pay Program may be able to provide assistance with their copay for many Lilly Oncology drugs, as listed in the Table.

The Lilly PatientOne Access Services program may be able to provide financial assistance, reimbursement assistance, or Lilly Oncology drugs at no cost to patients who are uninsured, underinsured, insured, denied a claim, or have difficulty affording their copay or coinsurance.

Lilly PatientOne Access Services also provides information on charitable assistance foundations that may be able to help underinsured patients. The Patient Assistance Program is provided by the Lilly Cares Foundation. The PatientOne program collects information on behalf of the Lilly Cares Foundation.


For patients who are prescribed Verzenio, Lilly Oncology provides support through its Verzenio Continuous Care program, which includes several support services.

Verzenio Continuous Care provides personalized support for patients who have been prescribed Verzenio, including access and financial assistance, by conducting benefits investigations and researching in-

network specialty pharmacy options to identify the lowest out-of-pocket cost available. It also offers patient support services, such as reinforcing Verzenio treatment information, and connecting patients with advocacy groups or disease- and treatment-related resources.

Verzenio Savings Card

The Verzenio Savings Card offers eligible, commercially insured patients free Verzenio for the first 3 months. After that period, the patient pays no more than $10 monthly, and this program pays eligible patients up to a maximum of $25,000 for a 12-month period.

The MyRightDose Dose Exchange Program allows patients who are prescribed Verzenio for an FDA-approved indication to continue Verzenio therapy at the appropriate dose, without delays or costs for the patient. Verzenio will be shipped to the patient after receipt of the enrollment form, at no cost, for up to 3 separate dose reductions between 5 and 28 days of therapy per exchange.


Reimbursement Assistance Criteria

To be eligible for reimbursement assistance, patients must:

  • Be permanent, legal residents of the United States or Puerto Rico
  • Take a qualifying Lilly Oncology drug within the United States.

Lilly PatientOne Co-Pay Program

To be eligible for this program, patients must:

  • Be aged ≥18 years and receive a prescription for an FDA-approved indication for 1 of the following drugs, including Alimta for injection, Cyramza, Erbitux, or Portrazza injection
  • Have commercial health insurance
  • Have an annual gross household income that does not exceed $100,000 or 500% of the federal poverty level.

Eligible patients who are enrolled in the Co-Pay Program pay ≤$25 per dose of Alimta, Cyramza, Erbitux, or Portrazza. For questions about patient eligibility requirements, call 866-472-8663.

Patient Assistance Program

The Patient Assistance Program provides patient assistance through the Lilly Cares Foundation. To be eligible for this program, patients must:

  • Meet the requirements for seeking reimbursement assistance
  • Receive ongoing treatment
  • Have no insurance, or have insurance that does not cover medications
  • Have an income ≤500% of the federal poverty level
  • Receive the medication within 180 days from the date Lilly PatientOne approves their application
  • Receive treatment in an outpatient setting.

Verzenio Continuous Care

To be eligible for the Verzenio Continuous Care program, patients must be aged ≥18 years, have been prescribed Verzenio for an FDA-approved indication, and meet the eligibility requirements.

Verzenio Savings Card

To be eligible for this program, patients must:

  • Have commercial health insurance
  • Not be eligible to have their prescription claims for Verzenio reimbursed, in whole or part, by any government-sponsored program, including Medicaid, Medicare, and Medicare Part D
  • Reside in the United States or Puerto Rico.

MyRightDose Dose Exchange Program

To be eligible for this program, patients must:

  • Return unused pills in the preaddressed envelope, according to the instructions provided
  • Be aged ≥18 years
  • Be a resident of the United States or Puerto Rico
  • Have a prescription for Verzenio for an FDA-approved indication.


Lilly PatientOne Access Services

To apply for Lilly Oncology patient support services or access services (reimbursement services, copay or coinsurance assistance, or no-cost Lilly Oncology drugs), only 1 application form needs to be completed and submitted.

The PatientOne Enrollment Form also includes the physician’s acknowledgment of medical necessity and the patient’s written authorization for the collection, use, and disclosure of his or her protected health information. Completed application forms should be faxed to 877-366-0585.

Verzenio Continuous Care

To enroll in this program, the prescriber and the patient must complete the enrollment form and fax it to 855-545-5957. To learn more about the Verzenio Continuous Care program, call 844-837-9364.

Verzenio Savings Card

Eligible patients can download or activate a Verzenio Savings Card online. For more information about this program, call 844-837-9364.

MyRightDose Dose Exchange Program

To enroll in this program, download the application and fax the completed form, with the prescribing physician’s signature, to 833-665-6329.


Patient support programs

Alimta (pemetrexed) for injection
Advanced NSCLC, as first-line treatment, in combination with cisplatin; advanced NSCLC, as monotherapy, after previous chemotherapy; unresectable malignant pleural mesothelioma, as initial treatment, in combination with cisplatin
Patient support programs

Cyramza (ramucirumab)
Metastatic gastric cancer, as monotherapy, or in combination with paclitaxel; metastatic NSCLC, in combination with docetaxel; metastatic colorectal cancer, in combination with irinotecan, folinic acid, and 5-fluorouracil; as monotherapy of hepatocellular carcinoma in patients with alpha fetoprotein of ≥400 mg/mL, after sorafenib therapy
Patient support programs

Gemzar (gemcitabine hydrochloride)
Advanced relapsed or refractory ovarian cancer; metastatic breast cancer, as first-line therapy; NSCLC; pancreatic cancer
Patient support program

Portrazza (necitumumab) injection
Advanced squamous NSCLC, in combination with gemcitabine and cisplatin
Patient support programs

Verzenio (abemaciclib)
As initial endocrine-based therapy, in combination with an aromatase inhibitor, for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, for disease that progressed after endocrine therapy; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, as monotherapy, for disease that progressed after endocrine therapy and previous chemotherapy in the metastatic setting
Patient support programs

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer.

Erbitux (cetuximab) Indications

Initial treatment of locally or regionally advanced squamous-cell carcinoma of the head and neck (SCCHN), in combination with radiation; first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN, in combination with platinum-based therapy; treatment of recurrent or metastatic SCCHN after failing platinum-based therapy; treatment of metastatic colorectal cancer that is EGFR-expressing, KRAS wild-type, as determined by an FDA-approved test, as first-line treatment, in combination with irinotecan, fluorouracil, and leucovorin, or in combination with irinotecan, in disease refractory to irinotecan-based chemotherapy or progressing after oxaliplatin- and irinotecan-based chemotherapy or intolerant to irinotecan

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: